Last reviewed · How we verify
NCT04952337: PROVID-CAPNETZ
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
trial in COVID-19 in 400 participants. Status unknown.
1 January 2022
Quick facts
| Lead sponsor | Hannover Medical School |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 October 2020 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 15 locations across Germany |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Viral Pneumonia — all drugs for Viral Pneumonia →
- Pneumonia Due to Streptococcus Pneumoniae — all drugs for Pneumonia Due to Streptococcus Pneumoniae →
- Bacterial Pneumonia — all drugs for Bacterial Pneumonia →
Sponsor
Hannover Medical School
Who can join
18 and older, any sex, with COVID-19 or Viral Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19. The aim of the joint project PROVID is to draw conclusions from the often very different clinical appearance of infections with the SARS-CoV-2 pathogen in order to improve patient care through targeted clinical management. The effects of infections with the SARS-CoV-2 pathogen are wide-ranging and include a spectrum from symptomlessness to infections of the upper respiratory tract, uncomplicated but also severe pneumonia with lung failure and high mortality. PROVID will first check whether certain host factors determine the severity and / or the course of Covid-19. Research is also being carried out into whether the molecular and clinical values of Covid-19 patients differ from those of patients with pneumonia caused by other pathogens. In addition, it will be tested whether specific molecular markers describe the severity of the disease and are suitable as an aid for targeted therapy for Covid-19. PROVID is an interdisciplinary joint project made up of three sub-projects that are being implemented at three locations (Charitè-Universitätsmedizin Berlin, Universität Leipzig IMISE and CAPNETZ STIFTUNG / Hannover). PROVID is based on three clinical research platforms with a high track record in recruiting patients with high-quality data and biomaterials on the one hand and guideline-changing results on the other hand: CAPNETZ (competence network CAP, since 2002, world's largest database and biobank for CAP), PROGRESS (Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis, since 2007) and CAPSyS (systems medicine of community-acquired pneumonia, since 2014). The COVID-19 patients are recruited into 3 different patient cohorts via these 3 research platforms. 1\. PROVID-CAPNETZ, 2. PROVID-PROGRESS, 3. PROVID-CAPSyS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study.
Meyer HJ, Mödl L, Unruh O, Xiang W, et al · · 2024 · cited 2× · PMID 38761325 · DOI 10.1007/s15010-024-02292-z
Verify or expand the search:
- PubMed search for NCT04952337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Hannover Medical School trials
Trials by the same sponsor.
- NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
- NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
- NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
- NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
- NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04952337 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
- Last refreshed: 7 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04952337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing